Despite the unavailability of Ozempic and Wegovy in India, the queries on the use and availability of the diabetes treatment drug continue to pour in on a daily basis for medical practitioners.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Sjc17xC
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» GLP1R-targeting drugs will continue to see demand due to pleiotropic benefits: Experts
https://ift.tt/gBKaEsj
No comments:
Post a Comment